Literature DB >> 12165171

NKT cells and type-1 diabetes and the "hygiene hypothesis" to explain the rising incidence rates.

Anjli Kukreja1, Noel K Maclaren.   

Abstract

Immune-mediated (type-1) diabetes (IMD) is a multigenetic disease that is strongly influenced by the environment. Whereas the incidence rates are steadily rising worldwide, less than half of affected identical twins ever become concordant for IMD or even beta-cell autoimmunity. Worldwide, it is the tropical regions of the world that are replete in infectious and parasitic diseases that are the least affected. Repeated efforts to identify the putative inductive agents for beta-cell autoimmunity have proved unrewarding. Rather, we suggest that some environments are less protective than others and argue that it is the fall in incidences of infectious diseases and intestinal parasites that are likely responsible for the rise in autoimmune diseases like IMD in the West. Nonobese diabetic (NOD) mice reared in gnotobiotic environments have only worsened diabetes, while recent studies suggest that multiple defects in immune tolerance to self must be present before IMD can develop in the human or mouse. We speculate herein that the deficiency in natural killer T (NKT) cells in IMD in both species may be both genetic and environmentally influenced, predisposing to pancreatic beta-cell autoimmunity through a dysfunction of immunoregulatory T cells, with defective peripheral control of islet cell protein autoreactive cytotoxic CD8+ T cells. The encouraging results in NOD mice using alpha-galactosylceramide to stimulate NKT cells now warrant trials with this and other glycolipid NKT cell-stimulating agents in humans. Since it has become apparent that autoimmune diseases such as IMD are the result of an underlying immunodeficiency state, we strongly argue that its effective prevention will likely come through the use of immunostimulation and not through side effect-prone immunosuppression.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12165171     DOI: 10.1089/152091502760098465

Source DB:  PubMed          Journal:  Diabetes Technol Ther        ISSN: 1520-9156            Impact factor:   6.118


  8 in total

1.  The glycolipid exoantigen derived from Chlamydia muridarum activates invariant natural killer T cells.

Authors:  Ying Peng; Lei Zhao; Sudhanshu Shekhar; Lu Liu; Hong Wang; Qiang Chen; Xiaoling Gao; Xi Yang; Weiming Zhao
Journal:  Cell Mol Immunol       Date:  2012-06-25       Impact factor: 11.530

Review 2.  Immunomodulation with microbial vaccines to prevent type 1 diabetes mellitus.

Authors:  Nikolai Petrovsky
Journal:  Nat Rev Endocrinol       Date:  2010-03       Impact factor: 43.330

Review 3.  The pathogenesis and natural history of type 1 diabetes.

Authors:  Mark A Atkinson
Journal:  Cold Spring Harb Perspect Med       Date:  2012-11-01       Impact factor: 6.915

4.  Epigenetic transgenerational actions of endocrine disruptors.

Authors:  Michael K Skinner; Mohan Manikkam; Carlos Guerrero-Bosagna
Journal:  Reprod Toxicol       Date:  2010-11-03       Impact factor: 3.143

5.  Characterization of human invariant natural killer T cells expressing FoxP3.

Authors:  Péter Engelmann; Klára Farkas; János Kis; Geoffrey Richman; Zhaoyun Zhang; Chong Wee Liew; Maciej Borowiec; Monika A Niewczas; Heyam Jalahej; Tihamér Orbán
Journal:  Int Immunol       Date:  2011-06-27       Impact factor: 4.823

6.  The threshold hypothesis: solving the equation of nurture vs nature in type 1 diabetes.

Authors:  C Wasserfall; K Nead; C Mathews; M A Atkinson
Journal:  Diabetologia       Date:  2011-07-20       Impact factor: 10.122

Review 7.  Potential role of NKT regulatory cell ligands for the treatment of immune mediated colitis.

Authors:  Madi El Haj; Ami Ben Ya'acov; Gadi Lalazar; Yaron Ilan
Journal:  World J Gastroenterol       Date:  2007-11-28       Impact factor: 5.742

Review 8.  Epigenetic transgenerational actions of environmental factors in disease etiology.

Authors:  Michael K Skinner; Mohan Manikkam; Carlos Guerrero-Bosagna
Journal:  Trends Endocrinol Metab       Date:  2010-01-14       Impact factor: 12.015

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.